← Atara Biotherapeutics, Inc. (ATRA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Atara Biotherapeutics, Inc. (ATRA)
Biological Products, (No Diagnostic Substances) · market cap $86M · as of 2026-07-14
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-11 (est.)
Earnings
Pipeline
3
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Atara Biotherapeutics (ATRA) is a micro-cap biotech with 38 employees and an $88M market cap, focused on EBV-specific cytotoxic T lymphocyte (EBV-CTL) therapies for EBV-induced lymphomas, both in Phase 2. The company carries only $8.4M in cash — roughly 8 months of runway — against a history of heavy R&D spend and cumulative losses exceeding $900M since 2021. The next scheduled event is an August 10, 2026 earnings release.
The catalyst path
- 2026-11-11 (est.)Earningsimp 5/10
- 2027-09-25 (est.)PDUFA · Ebvalloimp 8/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs) | Phase 2 | EBV-induced Lymphomas |
| EBV-specific T cells (EBV-CTLs) | Phase 2 | EBV-induced Lymphomas |
| CMV-pp65 CTLs | Phase 2 | Cytomegalovirus |
Price & technical context
3-month
-27.4%
6-month
+63.6%
12-month
-41.0%
52-wk range
$4.18–$18.09
vs 50-day MA
-5.3%
vs 200-day MA
+1.6%
Realized vol
142.6%
Max drawdown
-76.9%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ATRA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.